CD19 and acute lymphoblastic leukemia: Blinatumomab is a bispecific T-cell engager antibody simultaneously binding CTLs and CD19-positive BCP-ALL cells [24], suggesting that TRAIL/death receptor system may also be involved in anti-leukemic activities of blinatumomab.